Cohance Invests ₹110 Crore in Global Expansion

Cohance Lifesciences, backed by global private equity firm Advent International, has announced a strategic investment of ₹110 crore to expand its advanced therapeutic capabilities across Hyderabad, India, and New Jersey, USA.

The investment includes USD 10 million (approximately ₹87 crore) to enhance cGMP bioconjugation capabilities at its US-based subsidiary, NJ Bio, and ₹23 crore to establish a state-of-the-art cGMP manufacturing facility for oligonucleotide building blocks in Hyderabad.

The Hyderabad facility will focus on advanced chemistries, including modified nucleosides and locked nucleic acids (LNAs), supporting end-to-end manufacturing from laboratory scale to commercial volumes. Designed with a GMP production capacity of up to 700 kg per year and integrated with a pilot plant for early-stage synthesis, the unit aims to serve global innovators developing oligonucleotide-based therapeutics.

In parallel, the US investment will strengthen NJ Bio’s capabilities in delivering fully integrated antibody-drug conjugate (ADC) solutions, positioning Cohance as a comprehensive partner for next-generation modalities.

“These investments are aligned with our strategic vision to offer speed, flexibility, and quality across the development lifecycle of novel therapeutics,” said Vivek Sharma, Executive Chairman, Cohance Lifesciences. “By expanding our global footprint and deepening our technical expertise, we aim to become the partner of choice for biotech innovators worldwide.”

Together, the initiatives reinforce Cohance’s commitment to supporting emerging modalities with integrated, scalable solutions from early development through to late-stage clinical supply.

News by Rahul Yelligetti.